Day: April 29, 2020

Selskabsmeddelelse nr. 20Aalborg, 29. april 2020 Efter gensidig aftale fratræder Jesper Frank sin stilling som salgsdirektør for Seluxit den 8. maj 2020.Daniel Lux vil fremadrettet varetage ansvaret for salg og markedsføring i Seluxit.Når Seluxit har større afklaring i forhold til følgerne af COVID-19, vil vi vurdere hvordan salgsorganisation, der p.t. består af 4 medarbejdere, skal se ud.Daniel Lux, CEO:” Vi er kede af at Jesper Frank, fratræder som salgsdirektør for Seluxit. Jesper har arbejdet meget engageret, dedikeret og målrettet for Seluxit siden sin ansættelse, og vi har flyttet os i den rigtige retning. Jeg har stor respekt for Jesper, og jeg vil gerne sige tak for et spændende, udfordrende og udviklende år. Jeg giver Jesper vores bedste anbefalinger, og ønsker ham al mulig hel og lykke i sit fremtidige virke.”Jesper Frank, Salgsdirektør:“Jeg...

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Gold Lion Resources Inc. (“Gold Lion” or the “Company”) (CSE: GL) (OTC: GLIOF) (FWB: 2BC) is pleased to announce that it has mobilized exploration crews to its Robber Gulch gold Property (“Robber Gulch” or the “Property”) located near Burley, Idaho. The Property is under option from EMX Royalty Corp. A geochemical sampling program (>1200 soil samples) is being conducted over an area of prospective Pennsylvanian-Permian calcareous siltstones known as the Oquirrh Formation, which is host to gold mineralization 90 kilometers to the east on Liberty Gold’s Black Pine gold project1. The Oquirrh Formation is exposed within an erosional window of post-mineral volcanic rocks on Robber Gulch and to the best of the Company’s knowledge the Property has not had any prior soil geochemical...

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to announce that through its license partner, Moleculin Biotech, Inc. (NASDAQ: MBRX) (“Moleculin“), it has been authorized by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, known as URPL, to accelerate the Phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (“AML”).The URPL has allowed an amendment to the Annamycin clinical trial protocol, which among other things, includes an increase in the dose escalation increment between cohorts from 30 mg/m2 to 60 mg/m2. The clinical trial is currently recruiting suitable patients for the 240...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital socialMonthly information relating to the total number of voting rights and shares making up the share capitalArticle L. 233-8-II du Code de commerce et article 223-16 du Règlement général de l’AMFArticle L. 233-8 II of the French Commercial code and article 223-16 of the AMF General Regulation* Nombre de droits de vote exerçables = nombre de droits de vote théoriques (ou nombre total de droits de vote attachés aux actions) – actions privées du droit de vote** Number of effective voting rights = number of theoretical voting rights (or total number of voting rights attached to shares) – shares without voting rightsAttachmentWorldline – Voting rights and share capital – 31 March 2020

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital socialMonthly information relating to the total number of voting rights and shares making up the share capitalArticle L. 233-8-II du Code de commerce et article 223-16 du Règlement général de l’AMFArticle L. 233-8 II of the French Commercial code and article 223-16 of the AMF General Regulation* Nombre de droits de vote exerçables = nombre de droits de vote théoriques (ou nombre total de droits de vote attachés aux actions) – actions privées du droit de vote** Number of effective voting rights = number of theoretical voting rights (or total number of voting rights attached to shares) – shares without voting rightsPièce jointeWorldline – Droits de vote et nombre d’actions – 31 mars 2020

SHANGHAI, China, April 29, 2020 (GLOBE NEWSWIRE) — NIO Inc. (“NIO” or the “Company”) (NYSE: NIO), a pioneer in China’s premium smart electric vehicle market, today announced that it entered into definitive agreements for investments in NIO China with a group of investors (collectively, the “Strategic Investors”) led by Hefei City Construction and Investment Holding (Group) Co., Ltd., CMG-SDIC Capital Co., Ltd., and Anhui Provincial Emerging Industry Investment Co., Ltd.Under the definitive agreements, the Strategic Investors will invest an aggregate of RMB7 billion in cash into NIO (Anhui) Holding Ltd., the legal entity of NIO China. NIO will inject its core businesses and assets in China, including vehicle research and development, supply chain, sales and services and NIO Power (the “Asset Consideration”), into NIO China. The Asset...

     FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY1.         KEY INFORMATION2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER(a)        Purchases and sales(b)        Derivatives transactions (other than options)(c)        Options transactions in respect of existing securities(i)         Writing, selling, purchasing or varying(ii)        Exercising(d)        Other dealings (including subscribing for new securities)The currency of all prices and other monetary amounts should be stated.Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.3.         OTHER INFORMATION(a)       ...

Record results despite COVID-19 impact in Western EuropeFirst quarter 2020Net turnover amounted to SEK 7,450 M (6,874), an increase of 8 per cent.Operational earnings amounted to SEK 279 M (238).The figures were positively affected by strong growth in the Service Business, but negatively by fully or partially closed businesses in Western Europe, due to the spread of COVID-19 during March.Profit for the period amounted to SEK 167 M (154) and earnings per share to SEK 1.65 (1.50).Operating cash flow amounted to SEK 258 M (342). January – December 2019Net turnover amounted to SEK 29,508 M (28,382).Operational earnings amounted to SEK 1,239 M (1,034).Profit for the year amounted to SEK 807 M (734) and earnings per share to SEK 8.00 (7.25).Operating cash flow amounted to SEK 577 M (542).Events after the balance sheet dateSince the end of the...

Rekordresultat trots påverkan av Covid-19 i VästeuropaFörsta kvartalet 2020Nettoomsättningen uppgick till 7 450 Mkr (6 874), en ökning med 8 procent.Operativt rörelseresultat uppgick till 279 Mkr (238).Resultatet påverkades positivt av stark tillväxt i Serviceaffären men negativt av, helt eller delvis stängd verksamhet i Västeuropa, orsakat av Covid-19 spridningen under mars.Periodens resultat uppgick till 167 Mkr (154) och resultat per aktie till 1,65 kronor (1,50).Operativt kassaflöde uppgick till 258 Mkr (342).Januari-december 2019Nettoomsättningen uppgick till 29 508 Mkr (28 382).Operativt rörelseresultat uppgick till 1 239 Mkr (1 034).Årets resultat uppgick till 807 Mkr (734) och resultat per aktie till 8,00 kronor (7,25).Operativt kassaflöde uppgick till 577 Mkr (542).Händelser efter balansdagenEfter kvartalets slut har spridningen...

Company Announcement No 15/202029 April 2020Sydbank’s Interim Report – Q1 2020The first 3 months of 2020 were impacted by the negative effects of covid-19 and by a positive development in the Group’s core incomeQ1 2020 – highlightsProfit of DKK 55m equals a return on equity of 1.6% p.a. after tax.Core income of DKK 960m is 7% higher compared with the same period in 2019.Costs (core earnings) constitute DKK 718m and are unchanged compared to the same period in 2019.Impairment charges for loans and advances represent an expense of DKK 84m compared with an income of DKK 14m in the same period in 2019.Total credit intermediation amounts to DKK 145.0bn – the same level as at year-end 2019.At the coming AGM dividend distribution for 2019 will no longer be recommended. Consequently total capital has gone up by DKK 352m, equal to a 0.6 percentage...